ATTACKING CANCER METASTASIS

COARE Holdings Inc. is an OKC-based pre-clinical stage pharmaceutical company working to develop medications designed to treat late-stage solid tumor cancers. Metastatic cancers are by far the most prominent causes of mortality associated with nearly all solid tumor cancers. Colon, breast, ovarian, and pancreas are examples of tumors where safe and effective therapies that can prevent metastasis will fill a major unmet medical need.

"Current standard therapies for these solid tumor cancers often contain highly toxic cocktails that often dramatically reduce the quality of life of patients with minimal improvement in-patient survival. Moreover, many patients that experience effective initial responses often recur and experience metastasis due to the development of drug resistance," Courtney W. Houchen MD, co-founder of COARE Holdings Inc., said.

"Our exciting new platform technology is based on eliminating the cancer cells responsible for tumor growth metastasis and resistance to most chemo, radio and even the newer immunotherapies."

The approach COARE is using is based on a novel cellular based immunotherapy platform in combination with anti-proliferative targeted strategy that utilizes a personalized medicine scheme to overcome resistance and prevent metastasis in patients with late-stage solid tumor cancers. The technology was developed in the Houchen Lab at the University of Oklahoma Health Sciences Center, and is exclusively licensed to COARE Holdings Inc.

"We are extremely excited and poised to develop and commercialize this ground-breaking technology designed to improve the survival and reduce the overwhelming and often debilitating burden to families that have loved ones suffering from cancer," said Edwin Bannerman-Menson, CEO of COARE.

The term COARE was initially chosen to emphasize that a small subset of cells at the CORE of tumors are responsible for starting the tumor, helping the tumors grow and metastasize and these cells are the major cause of resistance to therapy. "The fundamental focus of COARE’s anticancer therapeutic program is based on their identification of the novel master regulatory protumorigenic protein Double Cortin like Kinase 1(DCLK1). DCLK1 is overexpressed in most solid tumor cancers and has been recently described as an exciting target for drug development," Bannerman-Menson said.

COARE is excited about the potential of their approach to finally attack the root cause of cancer metastasis while simultaneously overcoming drug resistance and reactivating the patient’s anti-tumor immunity thus fulfilling the major unmet medical need in cancer treatment. Holdings Inc. coareholdings.com